Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Healthtrust
Baxter
Boehringer Ingelheim
Daiichi Sankyo
Johnson and Johnson
Dow
Fuji
Cerilliant

Generated: May 25, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021205

« Back to Dashboard

NDA 021205 describes TRIZIVIR, which is a drug marketed by Viiv Hlthcare and is included in one NDA. It is available from two suppliers. There is one patent protecting this drug and one Paragraph IV challenge. Additional details are available on the TRIZIVIR profile page.

The generic ingredient in TRIZIVIR is abacavir sulfate; lamivudine; zidovudine. There are eleven drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the abacavir sulfate; lamivudine; zidovudine profile page.
Summary for 021205
Tradename:TRIZIVIR
Applicant:Viiv Hlthcare
Ingredient:abacavir sulfate; lamivudine; zidovudine
Patents:1
Therapeutic Class:Antivirals
Formulation / Manufacturing:see details
Pharmacology for NDA: 021205
Suppliers and Packaging for NDA: 021205
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
TRIZIVIR abacavir sulfate; lamivudine; zidovudine TABLET;ORAL 021205 NDA ViiV Healthcare Company 49702-217 N 49702-217-18
TRIZIVIR abacavir sulfate; lamivudine; zidovudine TABLET;ORAL 021205 NDA State of Florida DOH Central Pharmacy 53808-0990 E 53808-0990-1

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 300MG BASE;150MG;300MG
Approval Date:Nov 14, 2000TE:ABRLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Nov 14, 2018Product Flag?Substance Flag?Delist Request?Y

Expired US Patents for NDA 021205

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Viiv Hlthcare TRIZIVIR abacavir sulfate; lamivudine; zidovudine TABLET;ORAL 021205-001 Nov 14, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Viiv Hlthcare TRIZIVIR abacavir sulfate; lamivudine; zidovudine TABLET;ORAL 021205-001 Nov 14, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Viiv Hlthcare TRIZIVIR abacavir sulfate; lamivudine; zidovudine TABLET;ORAL 021205-001 Nov 14, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Viiv Hlthcare TRIZIVIR abacavir sulfate; lamivudine; zidovudine TABLET;ORAL 021205-001 Nov 14, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Cipla
Moodys
Fuji
US Department of Justice
Boehringer Ingelheim
Medtronic
Daiichi Sankyo
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.